Identification

Name
Polythiazide
Accession Number
DB01324
Type
Small Molecule
Groups
Approved
Description

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Renese
Categories
UNII
36780APV5N
CAS number
346-18-9
Weight
Average: 439.882
Monoisotopic: 438.970880311
Chemical Formula
C11H13ClF3N3O4S3
InChI Key
CYLWJCABXYDINA-UHFFFAOYSA-N
InChI
InChI=1S/C11H13ClF3N3O4S3/c1-18-10(4-23-5-11(13,14)15)17-7-2-6(12)8(24(16,19)20)3-9(7)25(18,21)22/h2-3,10,17H,4-5H2,1H3,(H2,16,19,20)
IUPAC Name
6-chloro-2-methyl-1,1-dioxo-3-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
CN1C(CSCC(F)(F)F)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O

Pharmacology

Indication

Polythiazide is a thiazide diuretic used to decrease edema and decrease blood pressure.

Structured Indications
Not Available
Pharmacodynamics

As a thiazide diuretic, Polythiazide inhibits the sodium-chloride symporter which decreases solute reabsorption leading to a retention of water in the urine, as water normally follows solutes. More frequent urination is due to the increased loss of water that has not been retained from the body as a result of a concomitant relationship with sodium loss from the convoluted tubule. The short-term anti-hypertensive action is based on the fact that thiazides decrease preload, decreasing blood pressure

Mechanism of action

As a diuretic, polythiazide inhibits active chloride reabsorption at the early distal tubule via the thiazide-sensitive Na-Cl cotransporter (TSC), resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like polythiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of polythiazide may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Polythiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Polythiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Polythiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Polythiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Polythiazide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Polythiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Polythiazide.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Polythiazide.Approved
AceclofenacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Polythiazide.Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Polythiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Polythiazide.Experimental
AlaproclateAlaproclate may increase the hyponatremic activities of Polythiazide.Experimental
AlclofenacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Polythiazide.Approved
AlcuroniumThe serum concentration of Polythiazide can be increased when it is combined with Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Polythiazide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Polythiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Polythiazide.Approved, Investigational
AliskirenPolythiazide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Polythiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Polythiazide.Approved
AlminoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Polythiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Polythiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Polythiazide.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Polythiazide.Approved, Withdrawn
AmbrisentanPolythiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Polythiazide.Approved
AmifostinePolythiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Polythiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved, Illicit
AndrographolideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Polythiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Polythiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Polythiazide.Investigational
AnisodamineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Polythiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Polythiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Polythiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Polythiazide.Investigational
AtenololAtenolol may increase the hypotensive activities of Polythiazide.Approved
AtracuriumThe serum concentration of Polythiazide can be increased when it is combined with Atracurium.Experimental
Atracurium besylateThe serum concentration of Polythiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Polythiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Polythiazide.Investigational
BalsalazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Polythiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Polythiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Polythiazide.Illicit
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Polythiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Polythiazide.Investigational
BenactyzineThe serum concentration of Polythiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilBenazepril may increase the hypotensive activities of Polythiazide.Approved, Investigational
BendazacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Polythiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Polythiazide.Withdrawn
BenorilateThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Polythiazide can be increased when it is combined with Benzatropine.Approved
BepridilBepridil may increase the hypotensive activities of Polythiazide.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Polythiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Polythiazide.Approved
BevoniumThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Polythiazide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Polythiazide.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Polythiazide.Approved, Investigational
BiperidenThe serum concentration of Polythiazide can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the hypotensive activities of Polythiazide.Approved
BornaprineThe serum concentration of Polythiazide can be increased when it is combined with Bornaprine.Experimental
BosentanBosentan may increase the hypotensive activities of Polythiazide.Approved, Investigational
BQ-123Polythiazide may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Polythiazide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Polythiazide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Polythiazide.Experimental
BromfenacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Polythiazide.Approved
BufexamacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Polythiazide.Withdrawn
BumadizoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bumadizone.Experimental
BupranololPolythiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Polythiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Polythiazide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Polythiazide.Experimental
CafedrinePolythiazide may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolPolythiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolPolythiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumPolythiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetatePolythiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonatePolythiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitratePolythiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionatePolythiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptatePolythiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconatePolythiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactatePolythiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Vet Approved
Calcium lactate gluconatePolythiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulatePolythiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamatePolythiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphatePolythiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.Approved
CandesartanCandesartan may increase the hypotensive activities of Polythiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Polythiazide.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Polythiazide.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Polythiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Polythiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Polythiazide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Polythiazide.Withdrawn
CarprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Polythiazide.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Polythiazide.Approved, Investigational
CaseinPolythiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Polythiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Polythiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Polythiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Polythiazide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Polythiazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Polythiazide.Approved, Investigational
CicletaninePolythiazide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Polythiazide.Experimental
CilazaprilPolythiazide may increase the hypotensive activities of Cilazapril.Approved
CitalopramCitalopram may increase the hyponatremic activities of Polythiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Polythiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Polythiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Polythiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Polythiazide.Approved
ClonidineClonidine may increase the hypotensive activities of Polythiazide.Approved
ClonixinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Clonixin.Approved
CloranololPolythiazide may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Polythiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Polythiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Polythiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Polythiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Polythiazide.Approved
CurcuminThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazidePolythiazide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Polythiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Polythiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with D-Limonene.Investigational
DapoxetineDapoxetine may increase the hyponatremic activities of Polythiazide.Investigational
DarifenacinThe serum concentration of Polythiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Polythiazide.Approved
DelaprilPolythiazide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Polythiazide.Investigational
DeserpidinePolythiazide may increase the hypotensive activities of Deserpidine.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Polythiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Polythiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Polythiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Polythiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Polythiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Polythiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Polythiazide.Vet Approved
DexetimideThe serum concentration of Polythiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Polythiazide.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Polythiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Polythiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Polythiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicyclomineThe serum concentration of Polythiazide can be increased when it is combined with Dicyclomine.Approved
diethylnorsperminePolythiazide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Polythiazide.Approved
DiflunisalThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Polythiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Polythiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Polythiazide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Polythiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Polythiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Polythiazide.Experimental, Illicit
DihydrotachysterolPolythiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Polythiazide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Polythiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Polythiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Polythiazide.Approved
DofetilidePolythiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Polythiazide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Polythiazide.Approved
DoxercalciferolPolythiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Polythiazide.Investigational
DroxicamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Polythiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Polythiazide.Approved
DuloxetineDuloxetine may increase the hyponatremic activities of Polythiazide.Approved
DuvelisibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Polythiazide can be decreased when used in combination with E-6201.Investigational
EfonidipinePolythiazide may increase the hypotensive activities of Efonidipine.Approved
EmeproniumThe serum concentration of Polythiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Polythiazide.Approved
EnalaprilEnalapril may increase the hypotensive activities of Polythiazide.Approved, Vet Approved
EnalaprilatPolythiazide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Polythiazide.Experimental
EpanololPolythiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Polythiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Epirizole.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Polythiazide.Approved
EprosartanEprosartan may increase the hypotensive activities of Polythiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Polythiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Polythiazide.Approved
ErgocalciferolPolythiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Polythiazide.Approved, Investigational
EstroneEstrone may increase the hypokalemic activities of Polythiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Polythiazide.Approved
EtanautineThe serum concentration of Polythiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Polythiazide.Approved
EthenzamideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Polythiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Polythiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Polythiazide.Approved
EtoricoxibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Polythiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Polythiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Polythiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Polythiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Polythiazide.Approved, Investigational
FenbufenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Polythiazide.Approved
FenoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Polythiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Polythiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Polythiazide can be increased when it is combined with Fesoterodine.Approved
FloctafenineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Polythiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Polythiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Polythiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Polythiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Polythiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Polythiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Polythiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Polythiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Polythiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Polythiazide.Approved
FlurbiprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Polythiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Polythiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Polythiazide.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Polythiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Polythiazide.Approved, Vet Approved
GallamineThe serum concentration of Polythiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Polythiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Polythiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Polythiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Polythiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Polythiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Polythiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Polythiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Polythiazide.Approved
GlycopyrroniumThe serum concentration of Polythiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Polythiazide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Polythiazide.Approved
GuanazodinePolythiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Polythiazide.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Polythiazide.Approved, Investigational
GuanoclorPolythiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPolythiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPolythiazide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Polythiazide.Investigational
HarmalineHarmaline may increase the hypotensive activities of Polythiazide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Polythiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Polythiazide.Approved, Illicit
HexamethoniumThe serum concentration of Polythiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
HigenamineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Polythiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Polythiazide.Experimental
HydralazineHydralazine may increase the hypotensive activities of Polythiazide.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Polythiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Polythiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Polythiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Polythiazide.Approved, Illicit
HyoscyamineThe serum concentration of Polythiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Polythiazide.Approved, Investigational
ImidaprilPolythiazide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Polythiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Polythiazide.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Polythiazide.Approved
IndenololPolythiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Polythiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Polythiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Polythiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Polythiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Polythiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Polythiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Polythiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Polythiazide.Approved
Ipratropium bromideThe serum concentration of Polythiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Polythiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Polythiazide.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Polythiazide.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Polythiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Polythiazide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Polythiazide.Approved
IsoxicamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Polythiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Polythiazide.Investigational
IvabradinePolythiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Polythiazide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Polythiazide.Approved
KetoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Polythiazide.Approved
LacidipinePolythiazide may increase the hypotensive activities of Lacidipine.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Polythiazide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Polythiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Polythiazide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Polythiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Polythiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Polythiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Polythiazide.Approved
LicoriceLicorice may increase the hypokalemic activities of Polythiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Polythiazide.Approved
LinsidominePolythiazide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Polythiazide.Approved
LisinoprilLisinopril may increase the hypotensive activities of Polythiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumPolythiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Polythiazide.Illicit
LofexidinePolythiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanLosartan may increase the hypotensive activities of Polythiazide.Approved
LoxoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanPolythiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipinePolythiazide may increase the hypotensive activities of Manidipine.Approved
MasoprocolThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Masoprocol.Approved
MazaticolThe serum concentration of Polythiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Polythiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Polythiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Polythiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Polythiazide.Approved
Mefenamic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Polythiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Polythiazide.Experimental
MesalazineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Polythiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Polythiazide.Approved, Illicit
MethanthelineThe serum concentration of Polythiazide can be increased when it is combined with Methantheline.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Polythiazide.Approved
MethoserpidinePolythiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Polythiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Polythiazide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Polythiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Polythiazide.Approved
MetixeneThe serum concentration of Polythiazide can be increased when it is combined with Metixene.Approved
MetolazoneMetolazone may increase the hypotensive activities of Polythiazide.Approved
MetoprololMetoprolol may increase the hypotensive activities of Polythiazide.Approved, Investigational
MetyrosinePolythiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilPolythiazide may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Polythiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Polythiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Polythiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Polythiazide.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Polythiazide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Polythiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Polythiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Polythiazide.Approved
MoexiprilMoexipril may increase the hypotensive activities of Polythiazide.Approved
MofebutazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Polythiazide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Polythiazide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Polythiazide.Approved
MuzoliminePolythiazide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Polythiazide.Approved
NafamostatThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilPolythiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Polythiazide.Approved
NaproxenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Polythiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Polythiazide.Investigational
NebivololPolythiazide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Polythiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Polythiazide.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Polythiazide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Polythiazide.Experimental
NicorandilPolythiazide may increase the hypotensive activities of Nicorandil.Approved
NifenazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipinePolythiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePolythiazide may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Polythiazide.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Polythiazide.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Polythiazide.Approved
NitroaspirinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Polythiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Polythiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Polythiazide.Approved, Illicit
ObinutuzumabPolythiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Polythiazide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Oleandrin.Experimental
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Polythiazide.Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Polythiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Polythiazide.Approved
OlopatadineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Polythiazide.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Polythiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Polythiazide.Approved
OrgoteinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Polythiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Polythiazide can be increased when it is combined with Otilonium.Experimental
OuabainThe risk or severity of adverse effects can be increased when Polythiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Polythiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Polythiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololPolythiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Polythiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Polythiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Polythiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Polythiazide can be increased when it is combined with Oxyphenonium.Approved
PancuroniumThe serum concentration of Polythiazide can be increased when it is combined with Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Polythiazide.Approved
ParecoxibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Polythiazide.Approved
ParicalcitolPolythiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Polythiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Parthenolide.Investigational
PenbutololPolythiazide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Polythiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Polythiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Polythiazide.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Polythiazide.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Polythiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Polythiazide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Polythiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Polythiazide.Approved, Withdrawn
PhenglutarimideThe serum concentration of Polythiazide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Polythiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Polythiazide.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Polythiazide.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Polythiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Polythiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Polythiazide.Withdrawn
PindololPindolol may increase the hypotensive activities of Polythiazide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Polythiazide.Approved, Investigational
PipecuroniumThe serum concentration of Polythiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Polythiazide.Approved
PirenzepineThe serum concentration of Polythiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Polythiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Polythiazide.Approved
PiroxicamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Polythiazide.Withdrawn
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Polythiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pranoprofen.Experimental
PrasteronePrasterone may increase the hypokalemic activities of Polythiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Polythiazide.Investigational
PrazosinPrazosin may increase the hypotensive activities of Polythiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Polythiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Polythiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Polythiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Polythiazide.Approved
ProcyclidineThe serum concentration of Polythiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Polythiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Polythiazide can be increased when it is combined with Propiverine.Investigational
PropranololPropranolol may increase the hypotensive activities of Polythiazide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Polythiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Polythiazide can be decreased when used in combination with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Polythiazide.Approved, Investigational
QuinidineThe serum concentration of Polythiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Polythiazide.Approved
RamiprilRamipril may increase the hypotensive activities of Polythiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Polythiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Polythiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Polythiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Polythiazide.Approved, Investigational
RescinnaminePolythiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Polythiazide.Approved
ResveratrolThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Polythiazide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Polythiazide.Approved
RiociguatPolythiazide may increase the hypotensive activities of Riociguat.Approved
RitodrineRitodrine may increase the hypokalemic activities of Polythiazide.Approved
RituximabPolythiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Polythiazide.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Polythiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Polythiazide.Approved
SalsalateThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanPolythiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Polythiazide.Approved
ScopolamineThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Polythiazide.Approved, Investigational, Vet Approved
SelexipagPolythiazide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Polythiazide.Approved
SildenafilSildenafil may increase the antihypertensive activities of Polythiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Polythiazide.Approved, Investigational
SitaxentanPolythiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphatePolythiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Polythiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Polythiazide.Investigational
SpiraprilPolythiazide may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Polythiazide can be decreased when used in combination with SRT501.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Polythiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Polythiazide.Approved, Investigational
TalinololPolythiazide may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Polythiazide.Approved
TarenflurbilThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Polythiazide.Approved, Investigational
TemocaprilPolythiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Polythiazide.Approved
TeriflunomideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinPolythiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatinePolythiazide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalinePolythiazide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Polythiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Polythiazide.Approved, Vet Approved
Tiaprofenic acidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TibolonePolythiazide may increase the hypotensive activities of Tibolone.Approved
TicrynafenPolythiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Polythiazide.Experimental
TimololTimolol may increase the hypotensive activities of Polythiazide.Approved
TinoridineThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Polythiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Polythiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Polythiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Polythiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Polythiazide.Approved
Tolfenamic AcidThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolmetin.Approved
TolonidinePolythiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Polythiazide.Approved
TolterodineThe serum concentration of Polythiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramatePolythiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Polythiazide.Approved
ToremifenePolythiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Polythiazide.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Polythiazide.Approved
TranilastThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Polythiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Polythiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Polythiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Polythiazide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Polythiazide.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Polythiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Polythiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Polythiazide.Experimental
TrimethaphanThe serum concentration of Polythiazide can be increased when it is combined with Trimethaphan.Approved
TriptolideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Polythiazide.Withdrawn
TropatepineThe serum concentration of Polythiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Polythiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Polythiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Polythiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Polythiazide.Approved, Investigational
UnoprostonePolythiazide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Polythiazide.Investigational
ValdecoxibThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Polythiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Polythiazide.Approved
VecuroniumThe serum concentration of Polythiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Polythiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Polythiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Polythiazide.Approved, Investigational
VincaminePolythiazide may increase the hypotensive activities of Vincamine.Experimental
VinpocetinePolythiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Polythiazide.Approved, Investigational
XipamidePolythiazide may increase the hypotensive activities of Xipamide.Experimental
XylometazolinePolythiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Polythiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Polythiazide.Withdrawn
ZofenoprilPolythiazide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15419
KEGG Drug
D00657
KEGG Compound
C07766
PubChem Compound
4870
PubChem Substance
46508633
ChemSpider
4704
ChEBI
8327
ChEMBL
CHEMBL1587
Therapeutic Targets Database
DAP000751
PharmGKB
PA164748763
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
ATC Codes
C03AA05 — PolythiazideC03AB05 — Polythiazide and potassiumG01AE10 — Combinations of sulfonamides

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)214 °CPhysProp
logP1.90SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.264 mg/mLALOGPS
logP2.13ALOGPS
logP1.1ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.31ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity90.52 m3·mol-1ChemAxon
Polarizability37.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9884
Blood Brain Barrier-0.5727
Caco-2 permeable-0.6601
P-glycoprotein substrateSubstrate0.6985
P-glycoprotein inhibitor INon-inhibitor0.7714
P-glycoprotein inhibitor IINon-inhibitor0.8974
Renal organic cation transporterNon-inhibitor0.776
CYP450 2C9 substrateNon-substrate0.6019
CYP450 2D6 substrateNon-substrate0.8108
CYP450 3A4 substrateNon-substrate0.5091
CYP450 1A2 substrateNon-inhibitor0.7786
CYP450 2C9 inhibitorNon-inhibitor0.5713
CYP450 2D6 inhibitorNon-inhibitor0.8479
CYP450 2C19 inhibitorNon-inhibitor0.7738
CYP450 3A4 inhibitorInhibitor0.6198
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6625
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8224
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3534 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8884
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Sulfenyl compounds / Dialkylthioethers / Azacyclic compounds / Organopnictogen compounds / Organofluorides
show 4 more
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzothiadiazine (CHEBI:8327)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Monroy A, Plata C, Hebert SC, Gamba G: Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000 Jul;279(1):F161-9. [PubMed:10894798]
  3. Frindt G, McNair T, Dahlmann A, Jacobs-Palmer E, Palmer LG: Epithelial Na channels and short-term renal response to salt deprivation. Am J Physiol Renal Physiol. 2002 Oct;283(4):F717-26. [PubMed:12217863]

Drug created on June 30, 2007 11:21 / Updated on October 02, 2017 04:57